JP2006526644A - Hsp−90阻害剤を酵素インヒビターとのコンビネーションにおいて使用する疾患の治療方法 - Google Patents

Hsp−90阻害剤を酵素インヒビターとのコンビネーションにおいて使用する疾患の治療方法 Download PDF

Info

Publication number
JP2006526644A
JP2006526644A JP2006515006A JP2006515006A JP2006526644A JP 2006526644 A JP2006526644 A JP 2006526644A JP 2006515006 A JP2006515006 A JP 2006515006A JP 2006515006 A JP2006515006 A JP 2006515006A JP 2006526644 A JP2006526644 A JP 2006526644A
Authority
JP
Japan
Prior art keywords
inhibitor
aag
hsp90
enzyme inhibitor
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006515006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006526644A5 (cg-RX-API-DMAC7.html
Inventor
ロバート ジュニア ジョンソン
イーキン ゾウ
トーマス ミューラー
Original Assignee
コーザン バイオサイエンシス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーザン バイオサイエンシス インコーポレイテッド filed Critical コーザン バイオサイエンシス インコーポレイテッド
Publication of JP2006526644A publication Critical patent/JP2006526644A/ja
Publication of JP2006526644A5 publication Critical patent/JP2006526644A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006515006A 2003-05-30 2004-05-28 Hsp−90阻害剤を酵素インヒビターとのコンビネーションにおいて使用する疾患の治療方法 Abandoned JP2006526644A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47490603P 2003-05-30 2003-05-30
US10/856,696 US20050020557A1 (en) 2003-05-30 2004-05-27 Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
PCT/US2004/016889 WO2005000213A2 (en) 2003-05-30 2004-05-28 Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors

Publications (2)

Publication Number Publication Date
JP2006526644A true JP2006526644A (ja) 2006-11-24
JP2006526644A5 JP2006526644A5 (cg-RX-API-DMAC7.html) 2007-07-12

Family

ID=34083152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006515006A Abandoned JP2006526644A (ja) 2003-05-30 2004-05-28 Hsp−90阻害剤を酵素インヒビターとのコンビネーションにおいて使用する疾患の治療方法

Country Status (4)

Country Link
US (1) US20050020557A1 (cg-RX-API-DMAC7.html)
EP (1) EP1628623A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006526644A (cg-RX-API-DMAC7.html)
WO (1) WO2005000213A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9808507B2 (en) 2014-08-25 2017-11-07 Samsung Electronics Co., Ltd. Anti-c-Met/anti-Ang2 bispecific antibody
US9956244B2 (en) 2014-07-30 2018-05-01 Samsung Electronics Co., Ltd. Biomarker Hsp90 for predicting effect of a c-Met inhibitor

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) * 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
EP1638541B1 (en) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
ES2594874T3 (es) * 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
US7642275B2 (en) * 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080200488A1 (en) * 2005-08-11 2008-08-21 Manley Paul W Combinations Comprising a Protein Kinase Inhibitor Being a Pyrimidylaminobenzamide Compound and a Hsp90 Inhibitor Such as 17-Aag
CA2618628C (en) 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
EP1976835A2 (en) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080027047A1 (en) * 2006-05-25 2008-01-31 Weiwen Ying Compounds that modulate HSP90 activity and methods for identifying same
CA2667348A1 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using saha and bortezomib for treating multiple myeloma
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
US8266791B2 (en) * 2007-09-19 2012-09-18 The Charles Stark Draper Laboratory, Inc. Method of fabricating microfluidic structures for biomedical applications
US20090234332A1 (en) * 2008-03-17 2009-09-17 The Charles Stark Draper Laboratory, Inc Artificial microvascular device and methods for manufacturing and using the same
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
US9421315B2 (en) 2012-09-05 2016-08-23 The Charles Stark Draper Laboratory, Inc. Compact hydraulic manifold structure for shear sensitive fluids
US9656212B2 (en) 2013-01-08 2017-05-23 The Charles Stark Draper Laboratory, Inc. Compact hydraulic manifold structure for shear sensitive fluids
US9784396B2 (en) 2014-02-17 2017-10-10 The Charles Stark Draper Laboratory, Inc. Microfluidic manifold for shear sensitive fluids

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
ATE194767T1 (de) * 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
AU6833994A (en) * 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
PL189698B1 (pl) * 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6682758B1 (en) * 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6174875B1 (en) * 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
WO2001029025A2 (en) * 1999-10-19 2001-04-26 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2002060430A1 (en) * 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
PT1373215E (pt) * 2001-03-30 2006-12-29 Uni S Of A R By The S D Of H H Derivado de geldanamicina e metodo de tratamento de cancro utilizando o mesmo
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1420747A4 (en) * 2001-08-06 2010-06-02 Kosan Biosciences Inc ANSAMYCIN BENZOQUINONE

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956244B2 (en) 2014-07-30 2018-05-01 Samsung Electronics Co., Ltd. Biomarker Hsp90 for predicting effect of a c-Met inhibitor
US9808507B2 (en) 2014-08-25 2017-11-07 Samsung Electronics Co., Ltd. Anti-c-Met/anti-Ang2 bispecific antibody

Also Published As

Publication number Publication date
WO2005000213A2 (en) 2005-01-06
EP1628623A4 (en) 2008-11-26
WO2005000213A3 (en) 2006-04-13
US20050020557A1 (en) 2005-01-27
EP1628623A2 (en) 2006-03-01
WO2005000213A8 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
US20050020557A1 (en) Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050020556A1 (en) Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US7691838B2 (en) Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
EP1631267B1 (en) Method for treating diseases using hsp90-inhibiting agents in combination with antimetabolites
US20050026893A1 (en) Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050054625A1 (en) Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050054589A1 (en) Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
Banerji et al. The clinical applications of heat shock protein inhibitors in cancer-present and future
Chiosis et al. Hsp90: the vulnerable chaperone
US6872715B2 (en) Benzoquinone ansamycins
TWI334350B (en) Cancer treatment
JP5688288B2 (ja) がんの処置のための相乗的な医薬の組合せ
KR20170005106A (ko) 암을 치료하기 위한 약학적 조합물
EP1420747A2 (en) Benzoquinone ansamycins
US7378407B2 (en) Geldanamycin compounds and method of use
WO2023037173A1 (en) A pharmaceutical micronutrient composition for use to simultaneously improve nervous system function, cognitive ability and response to stressors
EP3720850A1 (en) New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
US20090176888A1 (en) Composition comprising phytosphingosine or derivative thereof
JP2019532937A (ja) Rnaポリメラーゼi阻害に基づく、がんの併用治療戦略
Kasibhatla et al. Small-molecule HSP90 Inhibitors: Applications in Cancer and Neurodegenerative Diseases
EP4370143A1 (en) A pharmaceutical micronutrient composition for use to simultaneously improve nervous system function, cognitive ability and response to stressors
CN100490800C (zh) 含17-aag的药物溶液制剂
JP2014091712A (ja) Hsp90阻害剤と抗腫瘍性タキサン化合物との組み合わせ
NZ551111A (en) Pharmaceutical solution formulations containing 17-AAG in a vehicle comprising ethanol, polyethoxylated castor oil, and a third component
JP2014091711A (ja) Hsp90阻害剤と抗腫瘍性白金錯体との組み合わせ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070523

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20090206